Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01243138
Other study ID # A2581186
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2011
Est. completion date April 2012

Study information

Verified date February 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.


Description:

This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained. Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.


Recruitment information / eligibility

Status Completed
Enrollment 4386
Est. completion date April 2012
Est. primary completion date April 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult aged 18 or above Exclusion Criteria: - Pregnant women and/or lactating mothers - Subjects presenting with any life threatening disease/condition

Study Design


Locations

Country Name City State
Algeria Pfizer Investigational Site Alger
Algeria Pfizer Investigational Site Bejaja
Algeria Pfizer Investigational Site Djelfa
Algeria Pfizer Investigational Site Laghouat
Algeria Pfizer Investigational Site M'Sila
Algeria Pfizer Investigational Site Relizane
Algeria Pfizer Investigational Site Saida
Algeria Pfizer Investigational Site Tebessa
Algeria Pfizer Investigational Site Tlemcen
Cameroon Pfizer Investigational Site Bafoussam
Cameroon Pfizer Investigational Site Douala Deido
Cameroon Pfizer Investigational Site Mbandjock
Cameroon Pfizer Investigational Site Njombe
Cameroon Pfizer Investigational Site Soa
Cameroon Pfizer Investigational Site Yaounde Cite Verte
Egypt Pfizer Investigational Site Alexandria
Egypt Pfizer Investigational Site Cairo
Egypt Pfizer Investigational Site Shiben Al Kom
Egypt Pfizer Investigational Site Tanta
Ghana Pfizer Investigational Site Accra
Ghana Pfizer Investigational Site Jachie-Ashanti
Ghana Pfizer Investigational Site Kumasi
Ghana Pfizer Investigational Site Sogakope V/R
Ghana Pfizer Investigational Site Takoradi
Jordan Pfizer Investigational Site Amman
Jordan Pfizer Investigational Site Irbid
Jordan Pfizer Investigational Site Salt
Kenya Pfizer Investigational Site Chongoria
Kenya Pfizer Investigational Site Nairobi
Kuwait Pfizer Investigational Site Adailiya
Kuwait Pfizer Investigational Site Fahaheel
Kuwait Pfizer Investigational Site Kuwait
Kuwait Pfizer Investigational Site Mishref
Kuwait Pfizer Investigational Site Qadesya
Kuwait Pfizer Investigational Site Yarmouk
Lebanon Pfizer Investigational Site Beirut
Lebanon Pfizer Investigational Site Jbeil, Lebanon
Lebanon Pfizer Investigational Site Jounieh
Lebanon Pfizer Investigational Site Tripoli
Nigeria Pfizer Investigational Site Abuja, FCT
Nigeria Pfizer Investigational Site Abuja, Garki
Nigeria Pfizer Investigational Site Calabar
Nigeria Pfizer Investigational Site Enugu
Nigeria Pfizer Investigational Site Keffi, Nassarawa
Saudi Arabia Pfizer Investigational Site Dammam
Saudi Arabia Pfizer Investigational Site Jeddah
Saudi Arabia Pfizer Investigational Site Jeddah 21573
Saudi Arabia Pfizer Investigational Site Makkah
Saudi Arabia Pfizer Investigational Site Riyadh
Saudi Arabia Pfizer Investigational Site Riyadh
Saudi Arabia Pfizer Investigational Site Yanbu
Senegal Pfizer Investigational Site Dakar Nabil Choucair
Senegal Pfizer Investigational Site Dakar Ouakam
Senegal Pfizer Investigational Site Kebemer
Senegal Pfizer Investigational Site Kedoungou
Senegal Pfizer Investigational Site Saint Louis
Senegal Pfizer Investigational Site Ziguinchor
South Africa Pfizer Investigational Site Halfway House Gauteng
South Africa Pfizer Investigational Site Kwa-Zulu Natal
South Africa Pfizer Investigational Site Mamelodi East Pretoria
South Africa Pfizer Investigational Site Mokopane Limpopo
South Africa Pfizer Investigational Site Rondebosch
South Africa Pfizer Investigational Site Sheshego Limpopo
South Africa Pfizer Investigational Site Sydenham, Durban Kwazulu-natal
Tunisia Pfizer Investigational Site Ariana
Tunisia Pfizer Investigational Site Bouficha
Tunisia Pfizer Investigational Site Messaadine
Tunisia Pfizer Investigational Site Sfax
Tunisia Pfizer Investigational Site Tunis
Tunisia Pfizer Investigational Site Zaghouan
United Arab Emirates Pfizer Investigational Site Abu Dhabi
United Arab Emirates Pfizer Investigational Site Al Ain
United Arab Emirates Pfizer Investigational Site Dubai
United Arab Emirates Pfizer Investigational Site Ras Al Khaima

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Countries where clinical trial is conducted

Algeria,  Cameroon,  Egypt,  Ghana,  Jordan,  Kenya,  Kuwait,  Lebanon,  Nigeria,  Saudi Arabia,  Senegal,  South Africa,  Tunisia,  United Arab Emirates, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension At the time of the first visit
Secondary Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population. At the time of the first visit
Secondary Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population. At the time of the first visit
Secondary Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups. At the time of the first visit
Secondary Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic. At the time of the first visit
Secondary Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic. At the time of the first visit
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2